Renoprotective Effects of DPP-4 Inhibitors
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins. DPP-4 is a u...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/10/2/246 |
| _version_ | 1797414497718108160 |
|---|---|
| author | Daiji Kawanami Yuichi Takashi Hiroyuki Takahashi Ryoko Motonaga Makito Tanabe |
| author_facet | Daiji Kawanami Yuichi Takashi Hiroyuki Takahashi Ryoko Motonaga Makito Tanabe |
| author_sort | Daiji Kawanami |
| collection | DOAJ |
| description | Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins. DPP-4 is a ubiquitous protein with exopeptidase activity that exists in cell membrane-bound and soluble forms. It has been shown that an increased renal DPP-4 activity is associated with the development of DKD. A series of clinical and experimental studies showed that DPP-4 inhibitors have beneficial effects on DKD, independent of their glucose-lowering abilities, which are mediated by anti-fibrotic, anti-inflammatory, and anti-oxidative stress properties. In this review article, we highlight the current understanding of the clinical efficacy and the mechanisms underlying renoprotection by DPP-4 inhibitors under diabetic conditions. |
| first_indexed | 2024-03-09T05:34:08Z |
| format | Article |
| id | doaj.art-0cb3dfd6cbcd4569a5a4c132174ad2cd |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-09T05:34:08Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-0cb3dfd6cbcd4569a5a4c132174ad2cd2023-12-03T12:29:43ZengMDPI AGAntioxidants2076-39212021-02-0110224610.3390/antiox10020246Renoprotective Effects of DPP-4 InhibitorsDaiji Kawanami0Yuichi Takashi1Hiroyuki Takahashi2Ryoko Motonaga3Makito Tanabe4Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka 814-0180, JapanDepartment of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka 814-0180, JapanDepartment of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka 814-0180, JapanDepartment of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka 814-0180, JapanDepartment of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine, Fukuoka 814-0180, JapanDiabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Dipeptidyl peptidase (DPP)-4 inhibitors are widely used in the treatment of patients with type 2 diabetes (T2D). DPP-4 inhibitors reduce glucose levels by inhibiting degradation of incretins. DPP-4 is a ubiquitous protein with exopeptidase activity that exists in cell membrane-bound and soluble forms. It has been shown that an increased renal DPP-4 activity is associated with the development of DKD. A series of clinical and experimental studies showed that DPP-4 inhibitors have beneficial effects on DKD, independent of their glucose-lowering abilities, which are mediated by anti-fibrotic, anti-inflammatory, and anti-oxidative stress properties. In this review article, we highlight the current understanding of the clinical efficacy and the mechanisms underlying renoprotection by DPP-4 inhibitors under diabetic conditions.https://www.mdpi.com/2076-3921/10/2/246DPP-4DPP-4 inhibitorsdiabetic kidney diseasediabetic nephropathy |
| spellingShingle | Daiji Kawanami Yuichi Takashi Hiroyuki Takahashi Ryoko Motonaga Makito Tanabe Renoprotective Effects of DPP-4 Inhibitors Antioxidants DPP-4 DPP-4 inhibitors diabetic kidney disease diabetic nephropathy |
| title | Renoprotective Effects of DPP-4 Inhibitors |
| title_full | Renoprotective Effects of DPP-4 Inhibitors |
| title_fullStr | Renoprotective Effects of DPP-4 Inhibitors |
| title_full_unstemmed | Renoprotective Effects of DPP-4 Inhibitors |
| title_short | Renoprotective Effects of DPP-4 Inhibitors |
| title_sort | renoprotective effects of dpp 4 inhibitors |
| topic | DPP-4 DPP-4 inhibitors diabetic kidney disease diabetic nephropathy |
| url | https://www.mdpi.com/2076-3921/10/2/246 |
| work_keys_str_mv | AT daijikawanami renoprotectiveeffectsofdpp4inhibitors AT yuichitakashi renoprotectiveeffectsofdpp4inhibitors AT hiroyukitakahashi renoprotectiveeffectsofdpp4inhibitors AT ryokomotonaga renoprotectiveeffectsofdpp4inhibitors AT makitotanabe renoprotectiveeffectsofdpp4inhibitors |